Compare Illumina, Inc. (ILMN) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Procter & Gamble Co — how do they compare? Illumina, Inc. trades at $192.38 (market cap $28.96B), while Procter & Gamble Co trades at $145.12 (market cap $340.39B). The key difference: Procter & Gamble Co is far larger — about 11.8× Illumina, Inc.'s market cap, and Procter & Gamble Co pays a 2.97% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | PG | |
|---|---|---|
Market Cap | $28.96B | $340.39B |
Sector | Health | Consumer Staples |
52-Week High | $205.10 | $167.18 |
52-Week Low | $91.00 | $138.10 |
Enterprise Value | $30.32B | $366.23B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Procter & Gamble (PG) trades at $145.21, down 0.39% on the day, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $1.43 exceeding expectations, and a robust 18.44% net income margin. Recent news highlights its dividend reliability and supply chain improvements, while analyst consensus is bullish with a $161.20 price target.
Outlook remains positive due to steady profitability and dividend growth, but risks include premium valuation and economic sensitivity. Investors may find value in its defensive qualities amid market volatility, though near-term upside could be limited by technical resistance and modest revenue growth projections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
